For Adverum Biotechnologies Inc. [ADVM], RBC Capital Mkts sees a rise to $24. What next?

Adverum Biotechnologies Inc. [NASDAQ: ADVM] stock went on an upward path that rose over 2.66% on Tuesday, amounting to a one-week price increase of more than 3.84%. Over the last 12 months, ADVM stock rose by 111.38%. The one-year Adverum Biotechnologies Inc. stock forecast points to a potential downside of -16.52. The average equity rating for ADVM stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.95 billion, with 73.80 million shares outstanding and 51.36 million shares in the current float. Compared to the average trading volume of 1.35M shares, ADVM stock reached a trading volume of 1276077 in the most recent trading day, which is why market watchdogs consider the stock to be active.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!


Guru’s Opinion on Adverum Biotechnologies Inc. [ADVM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADVM shares is $20.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADVM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Adverum Biotechnologies Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 13, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price from $13 to $21. The new note on the price target was released on May 05, 2020, representing the official price target for Adverum Biotechnologies Inc. stock. Previously, the target price had yet another raise to $17, while Goldman analysts kept a Buy rating on ADVM stock.

The Average True Range (ATR) for Adverum Biotechnologies Inc. is set at 1.84, with the Price to Sales ratio for ADVM stock in the period of the last 12 months amounting to 6514.76. The Price to Book ratio for the last quarter was 5.91, with the Price to Cash per share for the same quarter was set at 3.70.

ADVM Stock Performance Analysis:

Adverum Biotechnologies Inc. [ADVM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.84. With this latest performance, ADVM shares gained by 34.42% in over the last four-week period, additionally plugging by 130.83% over the last 6 months – not to mention a rise of 111.38% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADVM stock in for the last two-week period is set at 67.13, with the RSI for the last a single of trading hit 68.08, and the three-weeks RSI is set at 66.28 for Adverum Biotechnologies Inc. [ADVM]. The present Moving Average for the last 50 days of trading for this stock 17.14, while it was recorded at 22.91 for the last single week of trading, and 11.69 for the last 200 days.

Insight into Adverum Biotechnologies Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Adverum Biotechnologies Inc. [ADVM] shares currently have an operating margin of -27418.00. Adverum Biotechnologies Inc.’s Net Margin is presently recorded at -25794.40.

Return on Total Capital for ADVM is now -33.53, given the latest momentum, and Return on Invested Capital for the company is -31.87. Return on Equity for this stock declined to -34.29, with Return on Assets sitting at -29.57. When it comes to the capital structure of this company, Adverum Biotechnologies Inc. [ADVM] has a Total Debt to Total Equity ratio set at 18.55. Additionally, ADVM Total Debt to Total Capital is recorded at 15.64, with Total Debt to Total Assets ending up at 14.57. Long-Term Debt to Equity for the company is recorded at 16.18, with the Long-Term Debt to Total Capital now at 13.65.

Reflecting on the efficiency of the workforce at the company, Adverum Biotechnologies Inc. [ADVM] managed to generate an average of -$565,667 per employee.Adverum Biotechnologies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.90 and a Current Ratio set at 17.90.


With the latest financial reports released by the company, Adverum Biotechnologies Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.29/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADVM.

Adverum Biotechnologies Inc. [ADVM] Insider Position Details

There are presently around $2,028 million, or 80.01% of ADVM stock, in the hands of institutional investors. The top three institutional holders of ADVM stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7,272,714, which is approximately New of the company’s market cap and around 0.50% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 7,150,000 shares of the stock with an approximate value of $169.46 million in ADVM stocks shares; and VERSANT VENTURE MANAGEMENT, LLC, currently with $167.52 million in ADVM stock with ownership of nearly New of the company’s market capitalization.

88 institutional holders increased their position in Adverum Biotechnologies Inc. [NASDAQ:ADVM] by around 35,857,561 shares. Additionally, 50 investors decreased positions by around 4,883,734 shares, while 11 investors held positions by with 44,849,128 shares. The mentioned changes placed institutional holdings at 85,590,423 shares, according to the latest SEC report filing. ADVM stock had 37 new institutional investments in for a total of 23,922,833 shares, while 19 institutional investors sold positions of 1,190,901 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.